Krystal Biotech, Inc. (KRYS)

Krystal Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	89.16	10.93	-139.98	-69.57	-32.17
Depreciation & Amortization	6.71	5.91	3.39	2.77	1.85
Loss (Gain) From Sale of Assets	-	-100	-	-	0.03
Loss (Gain) From Sale of Investments	-6.07	-5.09	0.1	-	-
Stock-Based Compensation	49.13	39.93	33.23	15.32	3.27
Other Operating Activities	-1.05	-1.97	0.03	1.04	0.01
Change in Accounts Receivable	-62.71	-42.04	-	-	-
Change in Inventory	-11.91	-4.48	-	-	-
Change in Accounts Payable	1.01	-0.1	-1.25	0.71	0.78
Change in Other Net Operating Assets	59.15	8.09	3.91	1.79	0.13
Operating Cash Flow	123.42	-88.8	-100.57	-47.94	-26.08
Capital Expenditures	-4.24	-11.8	-52.98	-68.34	-14.84
Sale of Property, Plant & Equipment	-	100	-	-	-
Investment in Securities	-159.2	-5.56	-61.1	-158.43	3.66
Investing Cash Flow	-163.44	82.64	-114.08	-226.77	-11.18
Issuance of Common Stock	32.4	203.5	36	355.65	118.02
Repurchase of Common Stock	-5.39	-0.75	-0.65	-	-
Other Financing Activities	-	-	-	-7.96	-
Financing Cash Flow	27.01	202.75	35.35	347.69	118.02
Foreign Exchange Rate Adjustments	-0.46	-0.16	-0.04	-	-
Net Cash Flow	-13.46	196.43	-179.35	72.98	80.76
Free Cash Flow	119.18	-100.6	-153.55	-116.27	-40.93
Free Cash Flow Margin	41.02%	-198.43%	-	-	-
Free Cash Flow Per Share	4.01	-3.63	-6.02	-5.24	-2.18
Cash Income Tax Paid	5.67	-	-	-	-
Levered Free Cash Flow	96.46	-73.51	-90.02	-85.35	-19.98
Unlevered Free Cash Flow	96.46	-73.51	-90.02	-84.41	-19.98
Change in Net Working Capital	19.64	46.79	-2.15	-9.51	-10.37

Source: S&P Capital IQ. Standard template. Financial Sources.